Ipilimumab is a fully human monoclonal antibody IgG1kappa that blocks the inhibitory receptor cytotoxic T lymphocyte antigen 4 (CTLA-4) on T cells. Ipilimumab can be used in unresectable or metastatic melanoma (MM) studies[1].
Molecular Weight:
(145.38 kDa)
Purity:
99.88
CAS Number:
[477202-00-9]
Target:
CTLA-4
Application Notes:
MCE Product type: Inhibitory Antibodies
* VAT and and shipping costs not included. Errors and price changes excepted